A phase 4, open-label study to evaluate the safety and immunogenicity of DTaP5-HBV-IPV-Hib in children previously vaccinated with DTaP2-HBV-IPV-Hib or DTaP5-HBV-IPV-Hib (V419-016)
ABSTRACTDTaP5-HBV-IPV-Hib (Vaxelis®) is a hexavalent combination vaccine (HV) indicated in infants and toddlers for the prevention of diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and invasive disease due to Haemophilus influenzae type b. Switching between HVs during the childhood vacc...
Wedi'i Gadw mewn:
Prif Awduron: | , , , , , , , , , |
---|---|
Fformat: | Llyfr |
Cyhoeddwyd: |
Taylor & Francis Group,
2024-12-01T00:00:00Z.
|
Pynciau: | |
Mynediad Ar-lein: | Connect to this object online. |
Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|
Rhyngrwyd
Connect to this object online.3rd Floor Main Library
Rhif Galw: |
A1234.567 |
---|---|
Copi 1 | Ar gael |